Maze Therapeutics, Inc. Common Stock (MAZE) — Strategic Asset Allocation Index
Maze Therapeutics, Inc. Common Stock (MAZE) has a Strategic Asset Allocation Index of 18.5% as of June 2026. Strategic assets (PP&E of $- plus long-term investments of $83.82 Million) total $83.82 Million, measured against net assets of $453.12 Million. A higher index reflects capital-intensive or investment-heavy strategies where strategic assets dominate the equity base. See Maze Therapeutics, Inc. Common Stock (MAZE) balance sheet quality index to measure how much of total assets are equity-financed.
SAAI
Strategic Assets
PP&E
Net Assets
Maze Therapeutics, Inc. Common Stock Strategic Asset Allocation Index (2024–2025)
This chart shows how Maze Therapeutics, Inc. Common Stock's Strategic Asset Allocation Index has evolved across 2 annual periods from 2024 to 2025. As of June 2026, the index stands at 18.5%, representing strategic assets of $83.82 Million against net assets of $453.12 Million USD. For live market cap and overall valuation, see Maze Therapeutics, Inc. Common Stock (MAZE) market capitalisation.
Annual Strategic Asset Allocation Index for Maze Therapeutics, Inc. Common Stock (2024–2025)
The table below presents the year-by-year Strategic Asset Allocation Index for Maze Therapeutics, Inc. Common Stock from 2024 to 2025, covering 2 annual filings. Each row shows PP&E, long-term investments, strategic assets combined, net assets, the index percentage, and the change in percentage points compared to the prior year. See what is Maze Therapeutics, Inc. Common Stock's book value for net asset value and shareholders' equity analysis.
| Year | SAAI | Strategic Assets (USD) | PP&E | LT Investments | Net Assets | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | 5.1% | $18.11 Million | $- | $18.11 Million | $354.97 Million | ▲ +5.1 pp |
| 2024 | 0.0% | $0.00 | $- | $0.00 | $196.90 Million | — |